John Lechleiter, Eli Lilly chairman, president & CEO, breaks down his company's Q2 earnings, meeting revenue expectations of $5.6 billion. He also discusses several new drugs in phase three development.
Data is a real-time snapshot *Data is delayed at least 15 minutes Market Data Terms of Service
Global Business and Financial News, Stock Quotes, and Market Data and Analysis
More Comments
ADD COMMENTS
PREVIEW COMMENT